A number of T cell co-inhibitory molecules CTLA4, ICOS, CD274, PDCD1, and IDO were markedly downregulated by NPRL2 treatment which was in agreement with the data found in bioinformatics analysis in stomach cancer patients' samples (Pi et al., 2022). The gene discussed is CTLA4; the disease is gastric neoplasm.